Allspring Global Investments Holdings LLC Purchases 25,206 Shares of Corcept Therapeutics Incorporated $CORT

Allspring Global Investments Holdings LLC grew its position in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 11.7% during the 3rd quarter, HoldingsChannel reports. The fund owned 239,812 shares of the biotechnology company’s stock after purchasing an additional 25,206 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Corcept Therapeutics were worth $20,204,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Golden State Wealth Management LLC bought a new position in Corcept Therapeutics during the 2nd quarter valued at about $28,000. Huntington National Bank boosted its position in shares of Corcept Therapeutics by 54.0% during the second quarter. Huntington National Bank now owns 479 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 168 shares during the period. Employees Retirement System of Texas bought a new position in shares of Corcept Therapeutics during the second quarter valued at approximately $52,000. USA Financial Formulas bought a new position in shares of Corcept Therapeutics during the second quarter valued at approximately $56,000. Finally, Farther Finance Advisors LLC raised its holdings in shares of Corcept Therapeutics by 277.6% in the second quarter. Farther Finance Advisors LLC now owns 910 shares of the biotechnology company’s stock worth $67,000 after buying an additional 669 shares during the period. Institutional investors own 93.61% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on CORT shares. Zacks Research upgraded Corcept Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, December 15th. Wolfe Research downgraded Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 target price for the company. in a research report on Wednesday, December 31st. HC Wainwright lowered their target price on shares of Corcept Therapeutics from $145.00 to $90.00 and set a “buy” rating for the company in a research note on Friday. Truist Financial set a $50.00 price target on shares of Corcept Therapeutics in a research note on Wednesday. Finally, UBS Group began coverage on shares of Corcept Therapeutics in a report on Tuesday, December 16th. They set a “neutral” rating and a $95.00 price objective for the company. Four equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $80.83.

Insider Activity

In other Corcept Therapeutics news, insider William Guyer sold 20,000 shares of the stock in a transaction dated Tuesday, October 7th. The stock was sold at an average price of $89.94, for a total value of $1,798,800.00. Following the completion of the sale, the insider directly owned 5,287 shares in the company, valued at approximately $475,512.78. This trade represents a 79.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Sean Maduck sold 20,000 shares of the business’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $73.99, for a total value of $1,479,800.00. Following the sale, the insider owned 7,904 shares in the company, valued at $584,816.96. The trade was a 71.67% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 196,700 shares of company stock worth $15,474,198 in the last quarter. 20.50% of the stock is currently owned by corporate insiders.

Corcept Therapeutics Stock Up 9.8%

Corcept Therapeutics stock opened at $38.20 on Monday. The company has a quick ratio of 3.07, a current ratio of 3.14 and a debt-to-equity ratio of 0.01. The firm has a market cap of $4.02 billion, a P/E ratio of 43.41 and a beta of 0.23. The business has a fifty day moving average of $76.45 and a two-hundred day moving average of $74.83. Corcept Therapeutics Incorporated has a twelve month low of $32.99 and a twelve month high of $117.33.

Corcept Therapeutics (NASDAQ:CORT) last released its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.16 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.02). The company had revenue of $207.64 million during the quarter, compared to the consensus estimate of $223.78 million. Corcept Therapeutics had a return on equity of 15.99% and a net margin of 14.19%.The company’s revenue was up 13.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.41 earnings per share. On average, analysts forecast that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current fiscal year.

Key Stores Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Canaccord cut its price target from $140 to $99 but kept a “buy” rating, signaling some sell‑side conviction that there is still meaningful upside from current levels if the company resolves regulatory issues or demonstrates efficacy in follow‑up data. Benzinga
• Neutral Sentiment: Options implied volatility has surged, reflecting elevated uncertainty and trader interest; that can amplify price moves (both rebounds and further declines) and is likely contributing to today’s bounce as short squeezes / gamma flows unwind. Implied Volatility Surging for Corcept Stock Options
• Neutral Sentiment: Unusually large options trading was reported around CORT, consistent with the volatility spike; that activity can produce sharp intraday rallies even when fundamentals remain unchanged. Monitor open interest and large‑block trades for clues to whether the move is technical/speculative versus a change in fundamentals. Corcept Therapeutics Target of Unusually Large Options Trading (NASDAQ:CORT)
• Negative Sentiment: The FDA issued a Complete Response Letter for relacorilant, saying the agency needs additional evidence of effectiveness for treating hypercortisolism (Cushing’s). That CRL drove the prior ~50%+ collapse in the share price and is the core fundamental headwind — approval now requires more data or discussions with the FDA that could delay or derail the drug’s U.S. launch. Corcept Receives Complete Response Letter for Relacorilant
• Negative Sentiment: Multiple outlets summarize the practical impact: analysts and investors marked down valuations and the stock hit new lows after the FDA decision — this is an ongoing risk to revenue/cash‑flow forecasts if relacorilant was a key growth driver. Corcept Tanks on FDA’s CRL to Relacorilant NDA in Hypercortisolism
• Negative Sentiment: Kaplan Fox has alerted investors to a possible securities‑law investigation into Corcept, which can prolong downside pressure and raise potential legal/settlement expenses. This increases headline risk even if operational issues are later resolved. Kaplan Fox Alerts Investors of Corcept Therapeutics, Inc. (CORT) to an Investigation of Possible Securities Law Violations

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.